High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in ethiopian population

OMICS A Journal of Integrative Biology

Volumn 18, Issue 7, 2014, Pages 446-453

  Aklillu, Eleni ^a   Djordjevic, Natasa ^a,b   Carrillo, Juan Antonio ^c   Makonnen, Eyasu ^d   Bertilsson, Leif ^a   Ingelman Sundberg, Magnus ^e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b University of Kragujevac Medical Faculty   (Serbia)

^c UNIVERSITY OF EXTREMADURA   (Spain)

^d ADDIS ABABA UNIVERSITY   (Ethiopia)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1,7 DIMETHYLURIC ACID; CAFFEINE; CYTOCHROME P450 2A6; PARAXANTHINE; CYP2A6 PROTEIN, HUMAN;

ADULT; AFRICA; AFRICAN AMERICAN; ALLELE; ANCESTRY GROUP; ARTICLE; CHINESE; CONTROLLED STUDY; CYP2A6 GENE; ENZYME ACTIVITY; ETHIOPIA; ETHIOPIAN; ETHNICITY; FEMALE; GENDER; GENE; GENE CONVERSION; GENE DELETION; GENE DUPLICATION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; GEOGRAPHIC DISTRIBUTION; GHANAIAN; HUMAN; KENYA; KOREAN (PEOPLE); MALE; NIGERIA; NORMAL HUMAN; PHENOTYPE; POPULATION GENETICS; PRIORITY JOURNAL; SMOKING; SWEDEN; URINALYSIS; ADOLESCENT; BLACK PERSON; CHILD; ENZYME ACTIVATION; GENETIC ASSOCIATION; GENETICS; HEALTH SURVEY; METABOLISM; PRESCHOOL CHILD; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP2A6; ENZYME ACTIVATION; ETHIOPIA; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; PHENOTYPE; POPULATION SURVEILLANCE; RISK FACTORS; SWEDEN; YOUNG ADULT;

EID: 84904021102     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2013.0140     Document Type: Article

References (45)

1. Aklillu E, Carrillo JA, Makonnen E, Bertilsson L, and Ingelman- Sundberg M. (2003). Xanthine oxidase activity is influenced by environmental factors in Ethiopians. Eur J Clin Pharmacol 59, 533-536.
2. Aklillu E, Carrillo JA, Makonnen E, et al. (2003). Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: Characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 64, 659-669.
3. Aklillu E, Dandara C, and Bertilsson LCM. (2007). Pharmacogenetics of cytochrome P450s in African populations: Clinical and molecular evolutionary implications. In: Suarez- Kurtz G, ed. Pharmacogenomics in Admixed Populations. Austin, TX: Landes Bioscience, 99-119.
4. Aklillu E, Herrlin K, Gustafsson LL, Bertilsson L, and Ingelman- Sundberg M. (2002). Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics 12, 375-383.
5. Arab-Alameddine M, Di Iulio J, Buclin T, et al. (2009). Pharmacogenetics- based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther 85, 485-494.
6. Begas E, Kouvaras E, Tsakalof A, Papakosta S, and Asprodini EK (2007). In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomed Chromatogr 21, 190-200.
7. Benowitz NL, Lessov-Schlaggar CN, Swan GE, and Jacob P, 3rd. (2006). Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther 79, 480-488.
8. Benowitz NL, Perez-Stable EJ, Fong I, et al. (1999). Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther 291, 1196-1203.
9. Carrillo JA, Christensen M, Ramos SI, et al. (2000). Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther Drug Monit 22, 409-417.
10. di Iulio J, Fayet A, Arab-Alameddine M, et al. (2009). In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 19, 300-309.
11. Djordjevic N, Carrillo JA, Gervasini G, Jankovic S, and Aklillu E. (2010. ) In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population. Eur J Clin Pharmacol 66, 571-578.
12. Djordjevic N, Carrillo JA, van den Broek MP, et al. (2013). Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans. Drug Metab Pharmacokinet 28, 93-97.
13. Gebeyehu E, Engidawork E, Bijnsdorp A, et al. (2011). Sex and CYP3A5 genotype influence total CYP3A activity: High CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. Pharmacogenomics J 11, 130-137.
14. Ghotbi R, Gomez A, Milani L, et al. (2009). Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. Pharmacogenomics J 9, 208-217.
15. Gyamfi MA, Fujieda M, Kiyotani K, Yamazaki H, and Kamataki T. (2005). High prevalence of cytochrome P450 2A6&1A alleles in a black African population of Ghana. Eur J Clin Pharmacol 60, 855-857.
16. Habtewold A, Amogne W, Makonnen E, et al. (2011). Longterm effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother 66, 2350-2361.
17. Habtewold A, Amogne W, Makonnen E, et al. (2013). Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients. Pharmacogenomics J 13, 484-489.
18. Johnstone E, Benowitz N, Cargill A, et al. (2006). Determinants of the rate of nicotine metabolism and effects on smoking behavior. Clin Pharmacol Ther 80, 319-330.
19. Kadlubar S, Anderson JP, Sweeney C, et al. (2009). Phenotypic CYP2A6 variation and the risk of pancreatic cancer. JOP 10, 263-270.
20. Kandel DB, Hu MC, Schaffran C, Udry JR, and Benowitz NL. (2007). Urine nicotine metabolites and smoking behavior in a multiracial/multiethnic national sample of young adults. Am J Epidemiol 165, 901-910.
21. Kwara A, Lartey M, Sagoe KW, Kenu E, and Court MH. (2009). CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 23, 2101-2106.
22. Mahavorasirikul W, Tassaneeyakul W, Satarug S, et al. (2009). CYP2A6 genotypes and coumarin-oxidation phenotypes in a Thai population and their relationship to tobacco smoking. Eur J Clin Pharmacol 65, 377-384.
23. Mukonzo JK, Okwera A, Nakasujja N, et al. (2013). Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: A prospective cohort study. BMC Infect Dis 13, 261.
24. Mukonzo JK, Roshammar D, Waako P, et al. (2009). A novel polymorphism in ABCB1 gene, CYP2B6&6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol 68, 690-699.
25. Mwenifumbo JC, Lessov-Schlaggar CN, Zhou Q, et al. (2008). Identification of novel CYP2A6&1B variants: The CYP2A6& 1B allele is associated with faster in vivo nicotine metabolism. Clin Pharmacol Ther 83, 115-121.
26. Mwenifumbo JC, Sellers EM, and Tyndale RF. (2007). Nicotine metabolism and CYP2A6 activity in a population of black African descent: Impact of gender and light smoking. Drug Alcohol Depend 89, 24-33.
27. Nakajima M, Fukami T, Yamanaka H, et al. (2006). Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 80, 282-297.
28. Newton P, Suputtamongkol Y, Teja-Isavadharm P, et al. (2000). Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria. Antimicrob Agents Chemother 44, 972-977.
29. Ngaimisi E, Habtewold A, Minzi O, et al. (2013). Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: A parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS One 8, e67946.
30. Ngaimisi E, Mugusi S, Minzi O, et al. (2011). Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther 90, 406-413.
31. Ngaimisi E, Mugusi S, Minzi OM, et al. (2010). Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther 88, 676-684.
32. Nowell S, Sweeney C, Hammons G, Kadlubar FF, and Lang NP. (2002). CYP2A6 activity determined by caffeine phenotyping: Association with colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 11, 377-383.
33. Ogburn ET, Jones DR, Masters AR, et al. (2010). Efavirenz primary and secondary metabolism in vitro and in vivo: Identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos 38, 1218-1229.
34. Oscarson M, McLellan RA, Gullsten H, et al. (1999). Identification and characterisation of novel polymorphisms in the CYP2A locus: Implications for nicotine metabolism. FEBS Lett 460, 321-327.
35. Oscarson M, McLellan RA, Gullsten H, et al. (1999). Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett 448, 105-110.
36. Paschke T, Riefler M, Schuler-Metz A, et al. (2001). Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method. Toxicology 168, 259-268.
37. Pelkonen O, Rautio A, Raunio H, and Pasanen M. (2000). CYP2A6: A human coumarin 7-hydroxylase. Toxicology 144, 139-147.
38. Pitarque M, von Richter O, Oke B, et al. (2001). Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: Impairment of its promoter activity. Biochem Biophys Res Commun 284, 455-460.
39. Pitarque M, von Richter O, Rodriguez-Antona C, et al. (2004). A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity. Hum Mutat 23, 258-266.
40. Rao Y, Hoffmann E, Zia M, et al. (2000). Duplications and defects in the CYP2A6 gene: Identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 58, 747-755.
41. Sinues B, Fanlo A, Mayayo E, et al. (2008). CYP2A6 activity in a healthy Spanish population: Effect of age, sex, smoking, and oral contraceptives. Hum Exp Toxicol 27, 367-372.
42. Tomaszewski P, Kubiak-Tomaszewska G, and Pachecka J. (2008). Cytochrome P450 polymorphism-molecular, metabolic, and pharmacogenetic aspects. II. Participation of CYP isoenzymes in the metabolism of endogenous substances and drugs. Acta Pol Pharm 65, 307-318.
43. Wang J, Pitarque M, and Ingelman-Sundberg M. (2006). 3¢- UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression. Biochem Biophys Res Commun 340, 491-497.
44. Yusof W, and Hua GS. (2012). Gene, ethnic and gender influences predisposition of adverse drug reactions to artesunate among Malaysians. Toxicol Mech Methods 22, 184-192.
45. Zhu AZ, Binnington MJ, Renner CC, et al. (2013). Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobaccospecific nitrosamine bioactivation. Carcinogenesis 34, 93-101.